Background: Medicaid insurance in Georgia provides limited reimbursement for heart transplant (HT) and left ventricular assist devices (LVAD). We examined whether insurance type affects eligibility for and survival after receipt of HT or LVAD.
| INTRODUC TI ON
More than 100 000 Americans with end-stage heart failure (HF) are refractory to optimal medical therapy, with a 1-year survival of only 10%-25%. [1] [2] [3] Heart transplant (HT) and left ventricular assist devices (LVAD) have dramatically changed the management and prognosis of patients with end-stage HF. HT remains the therapy of choice, with a median conditional survival that now exceeds thirteen years, 4 and substantial improvements in quality of life and functional status compared to medical therapy. 4 The demand for HT, however, far outpaces the supply of donor organs. 5 Surgical treatment of HF with a LVAD has become standard of care to clinically stabilize patients who deteriorate while awaiting HT and to improve survival and quality of life in some patients ineligible for HT. 6, 7 Evaluation to determine eligibility for HT or LVAD is a rigorous process that thoroughly evaluates all medical comorbidities, as well as psychosocial and/or socioeconomic factors that would identify candidates at high risk for poor outcomes. Eligibility for HT or LVAD is determined using specific criteria endorsed by international organizations, 8, 9 in an effort to provide guidance to individual centers.
All noncardiac medical conditions are assessed that may limit survival independent of heart disease (ie, advanced renal or hepatic 
O R I G I N A L A R T I C L E
Impact of insurance type on eligibility for advanced heart failure therapies and survival dysfunction, uncontrolled diabetes, and peripheral vascular disease).
In addition, psychosocial and socioeconomic evaluation is recommended to assess the patient's available support systems to achieve maximal compliance with medical care after the HT or LVAD surgery.
Multiple prior studies have identified public insurance as a risk factor for inferior outcomes after HT, likely related to differences in access to healthcare providers and the costs of immunosuppressant medications. [10] [11] [12] [13] Prior data have confirmed that very few uninsured or underinsured patients receive HT in the United States (US), as most HT programs require adequate insurance coverage and financial resources to list patients for transplantation. 14, 15 Currently, little data exist on the impact that insurance has on outcomes after LVAD.
Moreover, as national databases that track HT and LVAD outcomes do not capture data on all patients evaluated for those therapies, it is very difficult to know how insurance impacts access to or eligibility for advanced HF therapies. 
| ME THODS

| Study population
We retrospectively examined all patients evaluated for advanced HF therapies at Emory University Hospital from January 1, 2012, to December 31, 2016 (N = 574). Patients who had previously received HT and were evaluated for retransplant during this period were excluded from the study (N = 5). Eligibility for HT or LVAD is determined using criteria specified in the Emory University Hospital 
| Study end-points
The primary end-point for this analysis was eligibility for HT/LVAD, while the secondary end-point was survival at 1 year from the date of initial evaluation. Those candidates who meet the specified criteria will be "listed" for HT, while those candidates who do not meet the specified criteria for HT will be considered for DT LVAD or considered ineligible for advanced HF therapies. Outcomes of advanced therapy evaluations and reasons for ineligibility were determined by medical record review. Survival was determined by medical record review and/or Social Security Death Index query. Patients were censored at the time of loss to follow-up or at the last date of follow-up on October 1, 2017.
| Study covariates
Information on demographic, psychosocial, socioeconomic, and med- 
| Statistical analysis
Data are presented as mean ± SD or N (%) of patients. Baseline characteristics were compared between patients according to insurance using one-way analysis of variance for continuous variables and the chi-square or Fisher's exact test for categorical variables.
Differences in outcomes of the evaluation (HT, DT LVAD, or ineligi- 
| RE SULTS
| Baseline characteristics
During the study period, 569 patients were evaluated for primary HT and/or LVAD implantation. The baseline characteristics of the cohort are displayed in Table 1 . The mean age was 51.7 ± 12.7 years, 391 (68.7%) patients were male, and 307 (54.0%) were Black.
Compared to patients with private or Medicare insurance, patients with Medicaid insurance were younger and more likely to be Black.
Medicaid patients had fewer medical comorbidities, including better renal function, lower BMI, and were less likely to have CAD and hypertension. There was no difference by insurance type in inotrope dependence or hemodynamics (including RA, PCW, and CI) at evaluation.
| Association of insurance type with eligibility for HT/LVAD
Overall, 218 (38.3%) patients were listed for HT, 71 (12.5%) received DT LVAD, and 280 (49.2%) were ineligible for advanced therapies. The outcome of the evaluation for HT/LVAD varied according to insurance type ( Figure 1 ). On univariate analysis, patients with Medicaid insurance were least likely to be eligible for any advanced therapies (P = .003). Patients with Medicaid insurance were least likely to receive DT LVAD (P = .004), while patients with Medicare insurance were least likely to be eligible for HT (P = .007). Other predictors of ineligibility for advanced therapies included female sex, BMI, serum albumin, and inotropic support.
Reasons for ineligibility for HT varied according to insurance type (Table 2) . Medicaid patients had a higher mean number of reasons documented for ineligibility for HT. Patients with Medicare were more likely to be ineligible due to medical comorbidities, while patients with Medicaid were more likely to have inadequate social support. To examine whether insurance status is a significant variable in determining eligibility for DT LVAD, we compared the differences in comorbidities in those patients ineligible for HT in (Table 4) .
Similarly, patients with Medicaid insurance were 89% less likely (OR 0.11, 95% CI 0.01-0.91; P = .04) than patients with Medicare insurance to be eligible for DT LVAD.
| Association of insurance type with survival
Overall, 336 (71.1%) patients evaluated for advanced HF therapies survived to 1 year after evaluation. Risk-adjusted survival dif- 
| Probability of survival in patients who were eligible for HT
Overall survival at 1 year was higher for patients listed for HT as compared to patients not listed (83.8% vs 62.6%, P < .0001).
Among patients listed for HT, there was no difference in survival by insurance type ( Figure 3A Albumin, g/dL 3.5 ± 0.6 3.4 ± 0.5 3.4 ± 0.7 .4
Total bilirubin, mg/dL 1.6 ± 1.3 1.6 ± 1.1 1.8 ± 1.3 .5
Creatinine, mg/dL 1.5 ± 0.7 1.6 ± 0.8 1. Values are N (%) or mean ± SD.
TA B L E 2 Primary reasons for ineligibility for HT in patients evaluated for advanced HF therapies according to insurance type (OMM). Survival was higher for patients who received DT LVAD vs OMM (77.8% vs 59.2%; P < .0001; Figure 4) . Presumably, Medicaid patients could benefit from the 18.6% survival advantage afforded to DT LVAD recipients if their insurance benefits afforded full access to this therapy.
| D ISCUSS I ON
In this single-center retrospective cohort analysis, we found that (i) patients with Medicare and Medicaid insurance were less likely to be eligible for HT than patients with private insurance, but there was no difference in survival among patients based on insurance type once they were listed for HT, (ii) patients with Medicaid insurance were significantly less likely than patients with private or Medicare insurance to be eligible for DT LVAD therapy, and (iii) Medicaid insurance was a predictor of lower survival among patients not listed for HT despite fewer medical comorbidities. As Medicaid patients generally had a more favorable medical profile, and were only slightly less likely to have inadequate social support than patients with private or Medicare insurance who received DT LVAD, we feel our data are highly suggestive that the Medicaid patients were 89%-92% less likely to receive DT LVAD due to lack of insurance coverage for this TA B L E 3 Comparison of comorbid conditions and reasons for HT ineligibility in those patients who received destination therapy left ventricular assist device (DT LVAD) compared to those considered ineligible for any advanced heart failure therapy
DT LVAD N = 71
Ineligible for Advanced Therapies Active substance abuse 7 (9.9) 11 (9.2) 9 (7.6) 3 (7.3) .9
BMI, body mass index; CI, cardiac index; CKD, chronic kidney disease; DT, destination therapy; eGFR, estimated glomerular filtration rate; LV, left ventricle; RA, right atrial pressure; PCWP, pulmonary capillary wedge pressure. *P < .05 between DT LVAD vs private. **P < .05, DT vs medicare. ***P < .05, DT vs Medicaid.
therapy. Our data confirm the importance of adequate insurance coverage on access to lifesaving medical therapies. As charity care services at our hospital pay for HT for patients with Medicaid insurance, their access to this therapy bypasses restrictions based on insurance as long as they meet other criteria. Moreover, if patients are eligible for HT, insurance type does not impact survival, presumably due to the comprehensive care offered once a patient is deemed eligible for the therapy. However, as charity care services have previously been unavailable for DT LVAD, Medicaid patients are less likely to be eligible for this treatment, with a profound negative impact on survival.
Previous studies have suggested disparities in access to heart and other solid organ transplants based on insurance type. In a retrospective review of United Network for Organ Sharing (UNOS) data, DuBay et al 13 found that patients with Medicaid received fewer HT than expected and were listed with more severe organ failure, suggesting listing at a later stage of illness. Studies of other solid organ transplants have shown clear differences in access by insurance type.
Patients with public insurance are less likely to be evaluated or listed for kidney and liver transplant [17] [18] [19] Although a similar proportion of patients with Medicaid and Medicare insurance were listed for HT in our cohort, the proportion was less than that of patients with private insurance, and the reasons patients were ineligible differed according to insurance type.
Patients with Medicaid may be less likely to be eligible for advanced HF therapies due to concern about psychosocial and financial risk factors which could negatively impact outcomes. In our study, patients with Medicaid were more likely to ineligible due to inadequate social support. As Medicaid patients are often younger in age, a stable "primary social support person" for HT may be more difficult to obtain for a variety of reasons, including young spouses or other family members who work full time, minor children who are unable to serve as primary support, or older parents who may also have chronic health issues. A recent meta-analysis of 32 studies with 9,102 subjects suggests that social support may be weakly and inconsistently associated with post-transplant medication adherence. 20 Still, most transplant programs consider adequate social support systems to be a requirement for transplant candidacy. Although previous studies have also reported increased likelihood of nonadherence among Medicaid patients after HT, 11, 21, 22 Heart Transplant N = 569 Model to determine odds of being eligible for heart transplant was run in the entire cohort. Model to determine odds of being eligible for destination therapy LVAD was only run in the patients determined to be ineligible for heart transplant. Models are adjusted for age, gender, race, heart failure etiology, body mass index, chronic kidney disease, albumin, and use of inotropes at discharge.
TA B L E 4
Multivariate logistic regression to determine odds of being eligible for heart transplant or destination therapy LVAD F I G U R E 2 Survival after initial evaluation for advanced therapies according to insurance type concerns about nonadherence did not differ by insurance type.
Moreover, inadequate financial resources were not a factor determining differences in eligibility for HT by insurance type in our cohort.
We found that Medicaid insurance was associated with an in- found that public insurance to be associated with decreased longterm survival after HT. 10, 12 Another recent study which stratified UNOS HT data by geographic region found that public insurance was most prevalent in region 3, which includes Georgia. for transplant. 26 Moreover, the ACA Medicaid expansion was associated with increased HT listings in African American patients, 27 a group that is overrepresented in terms of HF severity at our center and nationwide, and more likely to be underinsured. Coverage for HT for our patients with Medicaid was provided through hospital charity care; however, these patients do have prescription drug benefits through Medicaid that provide access to medication including maintenance immunosuppression. Georgia Medicaid provides limited reimbursement for LVAD implantation; however, there is limited to no coverage for the cost of supplies for driveline dressing changes, such that the out-of-pocket cost to patients may be substantial. As undertaking this scientific analysis, our hospital has agreed to provide charity care to help cover any unreimbursed costs of implantation as well as supplies for Medicaid patients requiring DT LVAD. Given the high cost of advanced heart failure therapies, adequate insurance coverage is critical to maintain equitable access to specialized medical and surgical therapies. In 2009, the national average cost of the index hospitalization for LVAD was $208,522
and for HT was $168,576. 28 Financial pressure on states may continue to place coverage for specialized medical services in jeopardy, as organ transplant is not included in the core medical services which must be covered by state Medicaid programs. For instance, in 2010
Arizona chose to eliminate Medicaid coverage for heart, lung, liver, bone marrow, and pancreas transplants in the face of a state budget deficit. 29 Although Arizona reinstituted these benefits after drawing national attention and criticism, transplant services remain at risk. our analysis does not address differences which may exist in referral to evaluation for advanced therapies.
In summary, our analysis demonstrates limited eligibility for DT LVAD for patients with Medicaid insurance, as well as an increased risk of death among patients with Medicaid insurance who are not listed for HT. Given the large and expanding economic burden of HF, it is critical to examine patterns of health resource use, associated impact on clinical outcomes, and disparities in access to lifesaving therapies. In order to determine whether increased access to advanced HF therapies is feasible for our state government, cost-effectiveness analyses should be performed, in addition to the design of patient-centered interventions that can be tested in future analyses to target access barriers specific to patients with Medicaid.
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